Update on Asthma Management Guidelines

Mo Med. 2024 Sep-Oct;121(5):364-367.

Abstract

The Global Initiative for Asthma (GINA) was established in 1993 and publishes a yearly global strategy to improve asthma awareness, prevention and management of asthma worldwide, based on a review of the most updated evidence. The current 2024 GINA update advises that all adults and adolescents with asthma receive inhaled corticosteroid (ICS)- containing medication and should not be treated with short acting beta agonist (SABA) alone. The 2024 GINA strategy divides treatment into two 'Tracks": Track 1 (preferred Track), the reliever is as-needed combination low dose ICS-formoterol; Track 2 uses SABA as the reliever along with a separate ICS inhaler. The updates also stress the importance that individuals with asthma should have a written asthma action plan, and asthma management should be tailored to the individual to help reduce the occurrence of serious exacerbations, fatalities, and hospitalizations.

MeSH terms

  • Administration, Inhalation
  • Adolescent
  • Adrenal Cortex Hormones* / administration & dosage
  • Adrenal Cortex Hormones* / therapeutic use
  • Adrenergic beta-Agonists / administration & dosage
  • Adrenergic beta-Agonists / therapeutic use
  • Adult
  • Anti-Asthmatic Agents* / administration & dosage
  • Anti-Asthmatic Agents* / therapeutic use
  • Asthma* / drug therapy
  • Formoterol Fumarate / administration & dosage
  • Formoterol Fumarate / therapeutic use
  • Humans
  • Practice Guidelines as Topic

Substances

  • Anti-Asthmatic Agents
  • Adrenal Cortex Hormones
  • Adrenergic beta-Agonists
  • Formoterol Fumarate